1. Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro, Wolfgang Schraut, Leonard Baidoo, Kevin E. Kip, Antonia R. Sepulveda, Marilyn Pesci, Janet Harrison, Scott E. Plevy 
Gastroenterology 
Volume 136, Issue 2, Pages e1 (February 2009)
DOI: /j.gastro
Copyright © 2009 AGA Institute Terms and Conditions

2. Figure 1
Percentage of patients in remission (endoscopic grade score of i0 or i1) vs recurrence (endoscopic grade score of i2, i3, or i4) of Crohn's disease at the 1-year endoscopic evaluation by random assignment to infliximab or placebo. Infliximab vs placebo: P =
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions

3. Figure 2
Endoscopic grade and percentage of patients with endoscopic recurrence of Crohn's disease at 1-year follow-up evaluation by random assignment to infliximab or placebo.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions

4. Figure 3
CDAI scores of individual study patients at baseline and throughout the 1-year follow-up period by random assignment to (A) infliximab (n = 10) vs (B) placebo (n = 13). Two infliximab patients had their last CDAI score carried forward beginning at weeks 30 and 46; 1 placebo patient had the last CDAI score carried forward beginning at week 36.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions